Toluna and Harris Interactive Deliver Weekly Polling for 2022 French Elections
6.4.2022 12:00:00 EEST | Business Wire | Press release
Toluna, the leading consumer insights provider and parent company of Harris Interactive and KuRunData, today announced a joint initiative with Harris Interactive in service of the French Presidential and Legislative elections.
The companies are conducting weekly polling to measure French citizens on their preferred candidates, voting intention, and out-of-polling-station results. Harris Interactive has historically led this polling effort. However, this year, Harris Interactive is officially partnering with its sister company, Toluna, to cover the events. This year’s efforts include over 50 pre-election surveys with over 100,000 people interviewed, as well as 5,000 interviews on election day.
Harris Interactive and Toluna will also partner with leading French TV channel and radio station, M6 and RTL, throughout their coverage of the French elections. Harris Interactive and Toluna experts will first provide estimates of their weekly polling for the first and second rounds of the Presidential election, held Sunday, April 10, 2022, and Sunday, April 24, 2022.
The coverage will be live on M6 and RTL and will also be shared on Toluna and Harris Interactive social media networks from 12:00 PM CEST each election day and continuing throughout the day. The timeline will be as follows:
- 12:00 PM: Initial analysis of voter turnout
- 5:00 PM: Estimates of voter turnout
- 8:00 PM: Initial estimate of Presidential election results
- 8:30 PM onwards: Exclusive insights from “Voting Day” survey fielded by Harris Interactive and Toluna to understand voter motivations and abstentions
- Later in the evening: Refined results in real time
Following the Presidential election, Harris Interactive and Toluna will again work with M6 and RTL to deliver weekly polling for the French Legislative elections on June 12, 2022 and June 19, 2022, providing exclusive analysis and estimations of the French National Assembly’s composition.
The coverage will again feature live on M6 and RTL, available online throughout the evening, as well as on multiple social media channels, including:
- Harris Interactive: harris-interactive.fr / @HarrisInt_FR
- Toluna: tolunacorporate.com / @TolunaCorporate
- M6: groupem6.fr/ @M6, @M6Info, @M6Pro
- RTL: rtl.fr / @RTLFrance
Toluna CEO Frederic-Charles Petit, said: “We are thrilled to bring Toluna and Harris Interactive together to deliver our on-demand, real-time insights as part of this critical initiative in France’s political calendar. This is a great honor, and we look forward to delivering the accurate data the public desires.”
“Citizens today are bombarded with massive amounts of information during the election cycle, and it is essential that they have access to quality data as they evaluate candidates and results. For more than 20 years, Harris Interactive has been proud to deliver some of the most accurate measures of French election results, and we look forward to continuing this tradition in partnership with Toluna,” commented Jean-Daniel Lévy, Senior Vice President of Harris Interactive France and Director of Politics and Opinion Department.
About Toluna
Toluna delivers real-time consumer insights at the speed of the on-demand economy. Harris Interactive simplifies complex decisions with critical consumer intelligence. By fusing Harris’s sector expertise and award-winning research with Toluna’s innovative tools and technology, we strive to push market research toward a better tomorrow.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220406005266/en/
Contact information
Media Contact
Articulate Communications for Toluna
Audra Tiner
toluna@articulatecomms.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom